Stock Events

Stock Events

Mereo Biopharma Group 

€0.2560
89
+€0.00+0.79%Friday 20:46

Statistics

Day High
0.268
Day Low
0.25
52W High
1.92
52W Low
0.198
Volume
3,000
Avg. Volume
-
Mkt Cap
40.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-8,388.82%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
424,195Revenue
-35.58MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is ⁦0.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
0%
Sell
100%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MAH0.STU. It's not an investment recommendation.
NVIDIA
14
NVDA
Palantir Technologies
13
PLTR
Amazon
11
AMZN
AMD
11
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.85B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Mereo's focus on rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap29.4B
Alnylam Pharmaceuticals is a leader in the development of RNAi therapeutics, targeting genetic disorders which overlap with Mereo's therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, including cystic fibrosis, competing in the rare disease market.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is known for its development of medicines for rare diseases, directly competing with Mereo's market.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is focused on the development of gene-based therapies for serious diseases, including rare genetic disorders, competing with Mereo's gene therapy approach.
Novo Nordisk
NVO
Mkt Cap164.79B
Novo Nordisk is a global healthcare company with a strong focus on diabetes and other serious chronic conditions, but its biopharmaceutical segment also explores treatments that could compete with Mereo.
PTC Therapeutics
PTCT
Mkt Cap5.3B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines that target rare disorders, directly competing with Mereo Biopharma's focus.

About

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Show More
CEO
Denise Vera Scots-Knight
Employees
39
Country
United Kingdom
ISIN
US5894921072
WKN
000A2PEYJ

Listings

STU
DE
MAH0.STU
MU
DE
MAH0.MU
BOATS
BOATS
MREO.BOATS
F
DE
MAH0.F

0 Comments

Share your thoughts

FAQs

What is Mereo Biopharma Group stock price today?▼
The current price of MAH0.STU is €0.26 EUR — it has increased by +0.79% in the past 24 hours. Watch Mereo Biopharma Group stock price performance more closely on the chart.
What is Mereo Biopharma Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Mereo Biopharma Group stocks are traded under the ticker MAH0.STU.
Is Mereo Biopharma Group stock price growing?▼
MAH0.STU stock has risen by +4.07% compared to the previous week, the month change is a -20.5% fall, over the last year Mereo Biopharma Group has showed a -83.95% decrease.
What is Mereo Biopharma Group market cap?▼
Today Mereo Biopharma Group has the market capitalization of 40.88M
What is Mereo Biopharma Group revenue for the last year?▼
Mereo Biopharma Group revenue for the last year amounts to 424,195 EUR.
What is Mereo Biopharma Group net income for the last year?▼
MAH0.STU net income for the last year is -35.58M EUR.
How many employees does Mereo Biopharma Group have?▼
As of November 1, 2026, the company has 39 employees.
In which sector is Mereo Biopharma Group located?▼
Mereo Biopharma Group operates in the Health & Wellness sector.
When did Mereo Biopharma Group complete a stock split?▼
Mereo Biopharma Group has not had any recent stock splits.
Where is Mereo Biopharma Group headquartered?▼
Mereo Biopharma Group is headquartered in LONDON, United Kingdom.